Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

Table 1

Summary of completed neoadjuvant chemotherapy trials.*

Clinical trials	Design	Drugs	Population	pCR rate
Silver et al. [12]	Phase II single arm	Cisplatin × 4	TNBC	6/28 (21%)
Byrski et al. [13]	Retrosp.	All; CMF; AD; AC/FAC; cisplatin	BRCA1 mut.	All: 24/102 (24%); CMF: 1/14 (7%); AD: 2/25 (8%); AC/FAC: 11/51 (22%); Cisplatin: 10/12 (83%)
Bear et al. [14]	Phase III random.	Arm 1A: D × 4 → AC × 4; Arm 1B: D + X × 4 → AC × 4; Arm 1C: D + G × 4 cycles → Ac × 4	HER2−	Arm 1A: 102/393 (26%); Arm 1B: 91/390 (23%); Arm 1C: 106/388 (27%)
Alba et al. [15]	Phase II random.	Arm A: EC × 4 cycles → D × 4; Arm B: EC × 4 cycles → D + Carbo × 4	Basal-like	Arm A: 14/46 (30%); Arm B: 14/47 (30%)
Zelnak et al. [16]	Phase II random.	Arm A: D × 4 cycles → X × 4; Arm B: D + X × 8 cycles.	HER2−	Arm A: 2/25 (8%); Arm B: 3/26 (12%); Arm A/B (TNBC): 4/21 (19%)
Von Minckwitz et al. [17]; Huober et al. [18]	Phase III random.	Arm 1 (responder): TAC × 4; Arm 2 (responder): TAC × 6; Arm 3 (nonresponder): TAC × 4; Arm 4 (nonresponder): VX × 4	Any breast cancer	Arm 1–4; TNBC: 77/198 (39%); Non-TNBC: 22/147 (15%)
Baselga et al. [19]	Phase II single arm	Ixabepilone × 4	Any breast cancer	TNBC: 11/42 (26%); Non-TNBC: 18/119 (15%)

*TNBC: triple-negative breast cancer; pCR: pathological complete response; M: methotrexate; F: 5-fluorouracil; Retrosp.: retrospective study; T: paclitaxel; Carbo: carboplatin; D: docetaxel; C: cyclophosphamide; A: doxorubicin; E: epirubicin; X: capecitabine; G: gemcitabine; V: vinorelbine.